Trial Profile

A retrospective, real world study of Nivolumab for outcomes in octogenarian French patients with Advanced Non-Small Cell Lung Cancer

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 20 Nov 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary)
Indications Non-small cell lung cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms UNIVOC

Most Recent Events

19 Nov 2020 Results assessing 3-year healthcare resource utilization and costs associated with previously treated aNSCLC patients who initiated nivolumab, presented at the 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
21 Sep 2020 Results presented at the 45th European Society for Medical Oncology Congress
18 Oct 2019 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com